Literature DB >> 2256439

Long-term outcome of TIAs, RINDs and infarctions with minimum residuum. A prospective study in Madrid.

L Calandre1, F Bermejo, J Balseiro.   

Abstract

A group of patients with transient ischemic attacks (65 cases), reversible ischemic neurologic deficits (37 cases) and infarctions with minimum residuum (41 cases) was included in a prospective follow-up for a mean period of 5.2 years. Most of the patients were treated with acetylsalicylic acid or other antiplatelet agents, or with anticoagulants. Principal complications during follow-up were: cerebral infarction, 15 cases (10.4%); cerebral hematoma, 2 (1.3%); transient ischemic attacks, 17, (11.8%); reversible ischemic neurologic deficits, 9 (6.2%); myocardial infarction, 4 (2.7%); and death, 11 (7.6%). The cumulative incidence for stroke or death was 6.2% for the first year and 14% for the fifth year. There were no significant risk factors for the occurrence of stroke or vascular death on time-related multivariate analysis (Cox). Disabling stroke was less frequent after infarctions with minimum residuum than after transient ischemic attacks or reversible ischemic neurologic deficits.

Entities:  

Mesh:

Year:  1990        PMID: 2256439     DOI: 10.1111/j.1600-0404.1990.tb01597.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  3 in total

1.  Transient ischaemic attacks: which patients are at high (and low) risk of serious vascular events?

Authors:  G J Hankey; J M Slattery; C P Warlow
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-08       Impact factor: 10.154

Review 2.  Antithrombotic management for transient ischemic attack and ischemic stroke (other than atrial fibrillation).

Authors:  J Donald Easton
Journal:  Curr Atheroscler Rep       Date:  2011-08       Impact factor: 5.113

3.  Recommendations for management of patients with carotid stenosis.

Authors:  Arijana Lovrencic-Huzjan; Tatjana Rundek; Michael Katsnelson
Journal:  Stroke Res Treat       Date:  2012-05-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.